

# BK Virus infections - Pipeline Insight, 2021

<https://marketpublishers.com/r/B3F85F324B66EN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: B3F85F324B66EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "BK Virus infections – Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in BK Virus infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### BK Virus infections Understanding

#### BK Virus infections: Overview

The BK virus was first isolated from the urine of a renal transplant recipient with ureteric stenosis in 1971. The BK virus is a member of the polyomavirus family. The BK virus rarely causes disease but is typically associated with patients who have had a kidney transplant; many people who are infected with this virus are asymptomatic. If symptoms do appear, they tend to be mild: respiratory infection or fever. It is known, however, that the virus is spread from person to person, and not from an animal source. It has been suggested that this virus may be transmitted through respiratory fluids or urine, since infected individuals periodically excrete virus in the urine. This virus can be diagnosed by a BKV blood test or a urine test for decoy cells, in addition to carrying out a biopsy in the kidneys. PCR techniques are often carried out to identify the virus. Unfortunately,

treatment options for BK virus infection are limited, and there is no effective prophylaxis.

'BK Virus infections - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the BK Virus infections pipeline landscape is provided which includes the disease overview and BK Virus infections treatment guidelines. The assessment part of the report embraces, in depth BK Virus infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, BK Virus infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence BK Virus infections R&D. The therapies under development are focused on novel approaches to treat/improve BK Virus infections.

### BK Virus infections Emerging Drugs Chapters

This segment of the BK Virus infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### BK Virus infections Emerging Drugs

#### ALVR105 (Viralym-M): AlloVir

Viralym-M targets five devastating viral pathogens: BK virus (BKV), Cytomegalovirus (CMV), Adenovirus (AdV), Epstein - Barr virus (EBV), and Human Herpesvirus 6 (HHV-6), and has the potential to transform care for transplant recipients. Viralym-M is designed to play an important role in providing bridging immunity between conditioning and reconstitution of their immune systems. The drug is currently in Phase III stage of

development for the treatment of patients with BK virus infections.

### MAU868: Amplyx Pharmaceuticals

MAU868 is a potent neutralizing monoclonal antibody with activity against BKV. BKV reactivation can occur following kidney transplantation and may result in BKV nephropathy, a leading cause of renal allograft loss. Amplyx executed an exclusive worldwide license agreement with Novartis under which the company has acquired the rights to the Phase 2 anti-BK virus (BKV) monoclonal antibody, MAU868, for the treatment and prevention of BKV disease. The company is conducting Phase 2 proof-of-concept clinical trials of MAU868 in BKV disease.

Further product details are provided in the report

### BK Virus infections: Therapeutic Assessment

This segment of the report provides insights about the different BK Virus infections drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in BK Virus infections

There are approx. 5+ key companies which are developing the therapies for BK Virus infections. The companies which have their BK Virus infections drug candidates in the most advanced stage, i.e. Phase III include, AlloVir.

#### Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

BK Virus infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### BK Virus infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BK Virus infections therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BK Virus infections drugs.

### BK Virus infections Report Insights

- BK Virus infections Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### BK Virus infections Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing BK Virus infections drugs?

How many BK Virus infections drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of BK Virus infections?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the BK Virus infections therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for BK Virus infections and their status?

What are the key designations that have been granted to the emerging drugs?

## Contents

Introduction

Executive Summary

BK Virus infections: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

BK Virus infections – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

BK Virus infections companies' collaborations, Licensing, Acquisition -Deal Value

Trends

BK Virus infections Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

ALVR105 (Viralym-M): AlloVir

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

MAU868: Amplyx Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early stage products (Phase I)

Comparative Analysis

SL V10: SL VAXiGEN

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

BK Virus infections Key Companies

BK Virus infections Key Products

BK Virus infections- Unmet Needs

BK Virus infections- Market Drivers and Barriers

BK Virus infections- Future Perspectives and Conclusion

BK Virus infections Analyst Views

BK Virus infections Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for BK Virus infections

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for BK Virus infections

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: BK Virus infections - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/B3F85F324B66EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3F85F324B66EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970